100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018
HB3680

 

Introduced , by Rep. Brandon W. Phelps

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/204  from Ch. 56 1/2, par. 1204

    Amends the Illinois Controlled Substances Act. Adds 3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (some trade or other name: pink; U-47700) as a Schedule I controlled substance.


LRB100 10855 RLC 21089 b

 

 

A BILL FOR

 

HB3680LRB100 10855 RLC 21089 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 204 as follows:
 
6    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
7    Sec. 204. (a) The controlled substances listed in this
8Section are included in Schedule I.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any of the following opiates, including their
11isomers, esters, ethers, salts, and salts of isomers, esters,
12and ethers, whenever the existence of such isomers, esters,
13ethers and salts is possible within the specific chemical
14designation:
15        (1) Acetylmethadol;
16        (1.1) Acetyl-alpha-methylfentanyl
17    (N-[1-(1-methyl-2-phenethyl)-
18    4-piperidinyl]-N-phenylacetamide);
19        (2) Allylprodine;
20        (3) Alphacetylmethadol, except
21    levo-alphacetylmethadol (also known as levo-alpha-
22    acetylmethadol, levomethadyl acetate, or LAAM);
23        (4) Alphameprodine;

 

 

HB3680- 2 -LRB100 10855 RLC 21089 b

1        (5) Alphamethadol;
2        (6) Alpha-methylfentanyl
3    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
5    propanilido) piperidine;
6        (6.1) Alpha-methylthiofentanyl
7    (N-[1-methyl-2-(2-thienyl)ethyl-
8    4-piperidinyl]-N-phenylpropanamide);
9        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10        (7.1) PEPAP
11    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12        (8) Benzethidine;
13        (9) Betacetylmethadol;
14        (9.1) Beta-hydroxyfentanyl
15    (N-[1-(2-hydroxy-2-phenethyl)-
16    4-piperidinyl]-N-phenylpropanamide);
17        (10) Betameprodine;
18        (11) Betamethadol;
19        (12) Betaprodine;
20        (13) Clonitazene;
21        (14) Dextromoramide;
22        (15) Diampromide;
23        (16) Diethylthiambutene;
24        (17) Difenoxin;
25        (18) Dimenoxadol;
26        (19) Dimepheptanol;

 

 

HB3680- 3 -LRB100 10855 RLC 21089 b

1        (20) Dimethylthiambutene;
2        (21) Dioxaphetylbutyrate;
3        (22) Dipipanone;
4        (23) Ethylmethylthiambutene;
5        (24) Etonitazene;
6        (25) Etoxeridine;
7        (26) Furethidine;
8        (27) Hydroxpethidine;
9        (28) Ketobemidone;
10        (29) Levomoramide;
11        (30) Levophenacylmorphan;
12        (31) 3-Methylfentanyl
13    (N-[3-methyl-1-(2-phenylethyl)-
14    4-piperidyl]-N-phenylpropanamide);
15        (31.1) 3-Methylthiofentanyl
16    (N-[(3-methyl-1-(2-thienyl)ethyl-
17    4-piperidinyl]-N-phenylpropanamide);
18        (32) Morpheridine;
19        (33) Noracymethadol;
20        (34) Norlevorphanol;
21        (35) Normethadone;
22        (36) Norpipanone;
23        (36.1) Para-fluorofentanyl
24    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25    4-piperidinyl]propanamide);
26        (37) Phenadoxone;

 

 

HB3680- 4 -LRB100 10855 RLC 21089 b

1        (38) Phenampromide;
2        (39) Phenomorphan;
3        (40) Phenoperidine;
4        (41) Piritramide;
5        (42) Proheptazine;
6        (43) Properidine;
7        (44) Propiram;
8        (45) Racemoramide;
9        (45.1) Thiofentanyl
10    (N-phenyl-N-[1-(2-thienyl)ethyl-
11    4-piperidinyl]-propanamide);
12        (46) Tilidine;
13        (47) Trimeperidine;
14        (48) Beta-hydroxy-3-methylfentanyl (other name:
15    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16    N-phenylpropanamide).
17    (c) Unless specifically excepted or unless listed in
18another schedule, any of the following opium derivatives, its
19salts, isomers and salts of isomers, whenever the existence of
20such salts, isomers and salts of isomers is possible within the
21specific chemical designation:
22        (1) Acetorphine;
23        (2) Acetyldihydrocodeine;
24        (3) Benzylmorphine;
25        (4) Codeine methylbromide;
26        (5) Codeine-N-Oxide;

 

 

HB3680- 5 -LRB100 10855 RLC 21089 b

1        (6) Cyprenorphine;
2        (7) Desomorphine;
3        (8) Diacetyldihydromorphine (Dihydroheroin);
4        (9) Dihydromorphine;
5        (10) Drotebanol;
6        (11) Etorphine (except hydrochloride salt);
7        (12) Heroin;
8        (13) Hydromorphinol;
9        (14) Methyldesorphine;
10        (15) Methyldihydromorphine;
11        (16) Morphine methylbromide;
12        (17) Morphine methylsulfonate;
13        (18) Morphine-N-Oxide;
14        (19) Myrophine;
15        (20) Nicocodeine;
16        (21) Nicomorphine;
17        (22) Normorphine;
18        (23) Pholcodine;
19        (24) Thebacon.
20    (d) Unless specifically excepted or unless listed in
21another schedule, any material, compound, mixture, or
22preparation which contains any quantity of the following
23hallucinogenic substances, or which contains any of its salts,
24isomers and salts of isomers, whenever the existence of such
25salts, isomers, and salts of isomers is possible within the
26specific chemical designation (for the purposes of this

 

 

HB3680- 6 -LRB100 10855 RLC 21089 b

1paragraph only, the term "isomer" includes the optical,
2position and geometric isomers):
3        (1) 3,4-methylenedioxyamphetamine
4    (alpha-methyl,3,4-methylenedioxyphenethylamine,
5    methylenedioxyamphetamine, MDA);
6        (1.1) Alpha-ethyltryptamine
7    (some trade or other names: etryptamine;
8    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
9    3-(2-aminobutyl)indole; a-ET; and AET);
10        (2) 3,4-methylenedioxymethamphetamine (MDMA);
11        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
12    (also known as: N-ethyl-alpha-methyl-
13    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
14    and MDEA);
15        (2.2) N-Benzylpiperazine (BZP);
16        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
17        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
18        (4) 3,4,5-trimethoxyamphetamine (TMA);
19        (5) (Blank);
20        (6) Diethyltryptamine (DET);
21        (7) Dimethyltryptamine (DMT);
22        (7.1) 5-Methoxy-diallyltryptamine;
23        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
24        (9) Ibogaine  (some trade and other names:
25    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
26    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]

 

 

HB3680- 7 -LRB100 10855 RLC 21089 b

1    indole; Tabernanthe iboga);
2        (10) Lysergic acid diethylamide;
3        (10.1) Salvinorin A;
4        (10.5) Salvia divinorum (meaning all parts of the plant
5    presently classified botanically as Salvia divinorum,
6    whether growing or not, the seeds thereof, any extract from
7    any part of that plant, and every compound, manufacture,
8    salts, isomers, and salts of isomers whenever the existence
9    of such salts, isomers, and salts of isomers is possible
10    within the specific chemical designation, derivative,
11    mixture, or preparation of that plant, its seeds or
12    extracts);
13        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
14        (12) Peyote (meaning all parts of the plant presently
15    classified botanically as Lophophora williamsii Lemaire,
16    whether growing or not, the seeds thereof, any extract from
17    any part of that plant, and every compound, manufacture,
18    salts, derivative, mixture, or preparation of that plant,
19    its seeds or extracts);
20        (13) N-ethyl-3-piperidyl benzilate (JB 318);
21        (14) N-methyl-3-piperidyl benzilate;
22        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
23    (also known as N-hydroxy-alpha-methyl-
24    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
25        (15) Parahexyl; some trade or other names:
26    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-

 

 

HB3680- 8 -LRB100 10855 RLC 21089 b

1    dibenzo (b,d) pyran; Synhexyl;
2        (16) Psilocybin;
3        (17) Psilocyn;
4        (18) Alpha-methyltryptamine (AMT);
5        (19) 2,5-dimethoxyamphetamine
6    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
7        (20) 4-bromo-2,5-dimethoxyamphetamine
8    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
9    4-bromo-2,5-DMA);
10        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
11    Some trade or other names: 2-(4-bromo-
12    2,5-dimethoxyphenyl)-1-aminoethane;
13    alpha-desmethyl DOB, 2CB, Nexus;
14        (21) 4-methoxyamphetamine
15    (4-methoxy-alpha-methylphenethylamine;
16    paramethoxyamphetamine; PMA);
17        (22) (Blank);
18        (23) Ethylamine analog of phencyclidine.
19    Some trade or other names:
20    N-ethyl-1-phenylcyclohexylamine,
21    (1-phenylcyclohexyl) ethylamine,
22    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
23        (24) Pyrrolidine analog of phencyclidine. Some trade
24    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
25    PHP;
26        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

 

 

HB3680- 9 -LRB100 10855 RLC 21089 b

1        (26) 2,5-dimethoxy-4-ethylamphetamine
2    (another name: DOET);
3        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
4    (another name: TCPy);
5        (28) (Blank);
6        (29) Thiophene analog of phencyclidine (some trade
7    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
8    2-thienyl analog of phencyclidine; TPCP; TCP);
9        (30) Bufotenine (some trade or other names:
10    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
11    3-(2-dimethylaminoethyl)-5-indolol;
12    5-hydroxy-N,N-dimethyltryptamine;
13    N,N-dimethylserotonin; mappine);
14        (31)  1-Pentyl-3-(1-naphthoyl)indole 
15    Some trade or other names: JWH-018; 
16        (32) 1-Butyl-3-(1-naphthoyl)indole 
17    Some trade or other names: JWH-073;  
18        (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- 
19    (2-iodophenyl)methanone 
20    Some trade or other names: AM-694;
21        (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
22    (2-methyloctan-2-yl)phenol 
23    Some trade or other names: CP 47,497 
24    and its C6, C8 and C9 homologs;
25        (34.5)  2-[(1R,3S)-3-hydroxycyclohexyl]-5- 
26    (2-methyloctan-2-yl)phenol), where side chain n=5;  

 

 

HB3680- 10 -LRB100 10855 RLC 21089 b

1    and homologues where side chain n=4, 6, or 7;  Some  
2    trade or other names: CP 47,497; 
3        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
4    (2-methyloctan-2-yl)-6a,7, 
5    10,10a-tetrahydrobenzo[c]chromen-1-ol
6    Some trade or other names: HU-210; 
7        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
8    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
9    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
10    salts, and salts of isomers; Some trade or other  
11    names: HU-210, Dexanabinol; 
12        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
13    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
14    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
15    Some trade or other names: HU-211;
16        (37) (2-methyl-1-propyl-1H-indol-
17    3-yl)-1-naphthalenyl-methanone 
18    Some trade or other names: JWH-015;
19        (38) 4-methoxynaphthalen-1-yl-
20    (1-pentylindol-3-yl)methanone 
21    Some trade or other names: JWH-081;
22        (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
23    Some trade or other names: JWH-122;
24        (40) 2-(2-methylphenyl)-1-(1-pentyl-
25    1H-indol-3-yl)-ethanone 
26    Some trade or other names: JWH-251;

 

 

HB3680- 11 -LRB100 10855 RLC 21089 b

1        (41) 1-(2-cyclohexylethyl)-3- 
2    (2-methoxyphenylacetyl)indole 
3    Some trade or other names: RCS-8, BTW-8 and SR-18; 
4        (42)  Any compound structurally derived from 
5    3-(1-naphthoyl)indole or 1H-indol-3-yl- 
6    (1-naphthyl)methane by substitution at the 
7    nitrogen atom of the indole ring by alkyl, haloalkyl, 
8    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
9    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
10    or 2-(4-morpholinyl)ethyl whether or not further 
11    substituted in the indole ring to any extent, whether 
12    or not substituted in the naphthyl ring to any extent.
13    Examples of this structural class include, but are
14    not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
15    and JWH-185;
16        (43)  Any compound structurally derived from 
17    3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
18    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
19    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
20    aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
21    or 2-(4-morpholinyl)ethyl, whether or not further 
22    substituted in the pyrrole ring to any extent, whether 
23    or not substituted in the naphthyl ring to any extent.
24    Examples of this structural class include, but are not
25    limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
26    JWH-368; 

 

 

HB3680- 12 -LRB100 10855 RLC 21089 b

1        (44)  Any compound structurally derived from 
2    1-(1-naphthylmethyl)indene by substitution 
3    at the 3-position of the indene ring by alkyl, haloalkyl, 
4    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
5    halide, alkyl aryl halide, 1-(N-methyl-
6    2-piperidinyl)methyl, or 2-(4-
7    morpholinyl)ethyl whether or not further substituted in
8    the indene ring to any extent, whether or not substituted
9    in the naphthyl ring to any extent. Examples of
10    this structural class include, but are not
11    limited to, JWH-176; 
12        (45)  Any compound structurally derived from 
13    3-phenylacetylindole by substitution at the 
14    nitrogen atom of the indole ring with alkyl, haloalkyl, 
15    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
16    halide, alkyl aryl halide, 1-(N-methyl-2-
17    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
18    whether or not further substituted in the indole ring
19    to any extent, whether or not substituted in the phenyl
20    ring to any extent. Examples of this structural
21    class include, but are not limited to, JWH-167,
22    JWH-250, JWH-251, and RCS-8; 
23        (46)  Any compound structurally derived from 
24    2-(3-hydroxycyclohexyl)phenol by substitution 
25    at the 5-position of the phenolic ring by alkyl, 
26    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 

 

 

HB3680- 13 -LRB100 10855 RLC 21089 b

1    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
2    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
3    whether or not substituted in the cyclohexyl ring to any
4    extent. Examples of this structural class
5    include, but are not limited to, CP 47,
6    497 and its C8 homologue (cannabicyclohexanol); 
7        (46.1) Benzoylindoles: Any compound 
8    containing a 3-(benzoyl) indole structure with 
9    substitution at the nitrogen atom of the 
10    indole ring by an alkyl, haloalkyl, alkenyl, 
11    cycloalkylmethyl, cycloalkylethyl, 
12    1-(N-methyl-2-piperidinyl)methyl, 
13    or 2-(4-morpholinyl)ethyl group 
14    whether or not further substituted 
15    in the indole ring to any extent and 
16    whether or not substituted in the phenyl ring 
17    to any extent. Examples of this structural class 
18    include, but are not limited, to, AM-630, 
19    AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; 
20        (47)  3,4-Methylenedioxymethcathinone 
21    Some trade or other names: Methylone; 
22        (48)  3,4-Methyenedioxypyrovalerone 
23    Some trade or other names: MDPV; 
24        (49)  4-Methylmethcathinone 
25    Some trade or other names: Mephedrone; 
26        (50)  4-methoxymethcathinone; 

 

 

HB3680- 14 -LRB100 10855 RLC 21089 b

1        (51)  4-Fluoromethcathinone; 
2        (52)  3-Fluoromethcathinone; 
3        (53)  2,5-Dimethoxy-4-(n)-propylthio- 
4    phenethylamine; 
5        (54)  5-Methoxy-N,N-diisopropyltryptamine; 
6        (55)  Pentedrone;  
7        (56)  4-iodo-2,5-dimethoxy-N-((2-methoxy 
8    phenyl)methyl)-benzeneethanamine 
9    (trade or other name: 25I-NBOMe); 
10        (57)  4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl) 
11    methyl]-benzeneethanamine (trade or other name: 
12    25C-NBOMe); 
13        (58)  4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl) 
14    methyl]-benzeneethanamine (trade or other name: 
15    25B-NBOMe); 
16        (59)  3-cyclopropoylindole with 
17    substitution at the nitrogen atom of the 
18    indole ring by alkyl, haloalkyl, alkenyl, 
19    cycloalkylmethyl, cycloalkylethyl, aryl 
20    halide, alkyl aryl halide, 
21    1-(N-methyl-2-piperidinyl)methyl, or 
22    2-(4-morpholinyl)ethyl, whether or not 
23    further substituted on the indole ring 
24    to any extent, whether or not substituted 
25    on the cyclopropyl ring to any extent: 
26    including, but not limited to, XLR11, 

 

 

HB3680- 15 -LRB100 10855 RLC 21089 b

1    UR144, FUB-144; 
2        (60)  3-adamantoylindole with 
3    substitution at the nitrogen atom of the 
4    indole ring by alkyl, haloalkyl, alkenyl, 
5    cycloalkylmethyl, cycloalkylethyl, 
6    aryl halide, alkyl aryl halide, 
7    1-(N-methyl-2-piperidinyl)methyl, or 
8    2-(4-morpholinyl)ethyl, whether or not 
9    further substituted on the indole ring to 
10    any extent, whether or not substituted on 
11    the adamantyl ring to any extent: including, 
12    but not limited to, AB-001; 
13        (61)  N-(adamantyl)-indole-3-carboxamide 
14    with substitution at the nitrogen atom of the 
15    indole ring by alkyl, haloalkyl, alkenyl, 
16    cycloalkylmethyl, cycloalkylethyl, aryl halide, 
17    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
18    or 2-(4-morpholinyl)ethyl, whether or not further 
19    substituted on the indole ring to any extent, whether 
20    or not substituted on the adamantyl ring to any 
21    extent: including, but not limited to, 
22    APICA/2NE-1, STS-135; 
23        (62)  N-(adamantyl)-indazole-3-carboxamide 
24    with substitution at a nitrogen atom of the indazole 
25    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
26    cycloalkylethyl, aryl halide, alkyl aryl halide, 

 

 

HB3680- 16 -LRB100 10855 RLC 21089 b

1    1-(N-methyl-2-piperidinyl)methyl, or 
2    2-(4-morpholinyl)ethyl, whether or not further 
3    substituted on the indazole ring to any extent, 
4    whether or not substituted on the adamantyl 
5    ring to any extent: including, but not limited 
6    to, AKB48, 5F-AKB48; 
7        (63)  1H-indole-3-carboxylic acid 8-quinolinyl 
8    ester with substitution at the nitrogen atom of the 
9    indole ring by alkyl, haloalkyl, alkenyl, 
10    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
11    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
12    2-(4-morpholinyl)ethyl, whether or not further 
13    substituted on the indole ring to any extent, 
14    whether or not substituted on the quinoline ring 
15    to any extent: including, but not limited to, PB22, 
16    5F-PB22, FUB-PB-22; 
17        (64)  3-(1-naphthoyl)indazole with 
18    substitution at the nitrogen atom of the 
19    indazole ring by alkyl, haloalkyl, 
20    alkenyl, cycloalkylmethyl, cycloalkylethyl, 
21    aryl halide, alkyl aryl halide, 
22    1-(N-methyl-2-piperidinyl)methyl, or 
23    2-(4-morpholinyl)ethyl, whether or not further 
24    substituted on the indazole ring to any extent, 
25    whether or not substituted on the naphthyl ring 
26    to any extent: including, but not limited to, 

 

 

HB3680- 17 -LRB100 10855 RLC 21089 b

1    THJ-018, THJ-2201; 
2        (65)  2-(1-naphthoyl)benzimidazole with 
3    substitution at the nitrogen atom of the benzimidazole 
4    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
5    cycloalkylethyl, aryl halide, alkyl aryl halide, 
6    1-(N-methyl-2-piperidinyl)methyl, or 
7    2-(4-morpholinyl)ethyl, whether or not further 
8    substituted on the benzimidazole ring to any extent, 
9    whether or not substituted on the naphthyl ring to 
10    any extent: including, but not limited to, FUBIMINA; 
11        (66)  N-(1-amino-3-methyl-1-oxobutan-2-yl) 
12    -1H-indazole-3-carboxamide with substitution on the 
13    nitrogen atom of the indazole ring by alkyl, 
14    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
15    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
16    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
17    whether or not further substituted on the indazole 
18    ring to any extent: including, but not limited to, 
19    AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
20        (67)  N-(1-amino-3,3-dimethyl-1-oxobutan- 
21    2-yl)-1H-indazole-3-carboxamide with substitution 
22    on the nitrogen atom of the indazole ring by alkyl, 
23    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
24    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
25    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether 
26    or not further substituted on the indazole ring to any 

 

 

HB3680- 18 -LRB100 10855 RLC 21089 b

1    extent: including, but not limited to,
2    ADB-PINACA, ADB-FUBINACA; 
3        (68)  N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
4    1H-indole-3-carboxamide with substitution on the nitrogen 
5    atom of the indole ring by alkyl, haloalkyl, alkenyl, 
6    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
7    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
8    2-(4-morpholinyl)ethyl, whether or not further 
9    substituted on the indole ring to any extent: 
10    including, but not limited to, ADBICA, 5F-ADBICA; 
11        (69)  N-(1-amino-3-methyl-1-oxobutan-2-yl)- 
12    1H-indole-3-carboxamide with substitution on the 
13    nitrogen atom of the indole ring by alkyl, haloalkyl, 
14    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
15    halide, alkyl aryl halide, 1-(N-methyl-2- 
16    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
17    whether or not further substituted on the indole 
18    ring to any extent: including, but not limited 
19    to, ABICA, 5F-ABICA; 
20        (70)  Methyl 2-(1H-indazole-3-carboxamido)- 
21    3-methylbutanoate with substitution on the nitrogen 
22    atom of the indazole ring by alkyl, haloalkyl, 
23    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
24    halide, alkyl aryl halide, 1-(N-methyl-2- 
25    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
26    whether or not further substituted on the indazole 

 

 

HB3680- 19 -LRB100 10855 RLC 21089 b

1    ring to any extent: including, but not
2    limited to, AMB, 5F-AMB; . 
3        (71) 3,4-Dichloro-N-[2-(dimethylamino) 
4    cyclohexyl]-N-methylbenzamide (Some trade or other 
5    name: pink; U-47700). 
6    (e) Unless specifically excepted or unless listed in
7another schedule, any material, compound, mixture, or
8preparation which contains any quantity of the following
9substances having a depressant effect on the central nervous
10system, including its salts, isomers, and salts of isomers
11whenever the existence of such salts, isomers, and salts of
12isomers is possible within the specific chemical designation:
13        (1) mecloqualone;
14        (2) methaqualone; and
15        (3) gamma hydroxybutyric acid.
16    (f) Unless specifically excepted or unless listed in
17another schedule, any material, compound, mixture, or
18preparation which contains any quantity of the following
19substances having a stimulant effect on the central nervous
20system, including its salts, isomers, and salts of isomers:
21        (1) Fenethylline;
22        (2) N-ethylamphetamine;
23        (3) Aminorex (some other names:
24    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
25    4-5-dihydro-5-phenyl-2-oxazolamine) and its
26    salts, optical isomers, and salts of optical isomers;

 

 

HB3680- 20 -LRB100 10855 RLC 21089 b

1        (4) Methcathinone (some other names:
2    2-methylamino-1-phenylpropan-1-one;
3    Ephedrone; 2-(methylamino)-propiophenone;
4    alpha-(methylamino)propiophenone; N-methylcathinone;
5    methycathinone; Monomethylpropion; UR 1431) and its
6    salts, optical isomers, and salts of optical isomers;
7        (5) Cathinone (some trade or other names:
8    2-aminopropiophenone; alpha-aminopropiophenone;
9    2-amino-1-phenyl-propanone; norephedrone);
10        (6) N,N-dimethylamphetamine (also known as:
11    N,N-alpha-trimethyl-benzeneethanamine;
12    N,N-alpha-trimethylphenethylamine);
13        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
14    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
15        (8) 3,4-Methylenedioxypyrovalerone (MDPV).
16    (g) Temporary listing of substances subject to emergency
17scheduling. Any material, compound, mixture, or preparation
18that contains any quantity of the following substances:
19        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
20    (benzylfentanyl), its optical isomers, isomers, salts,
21    and salts of isomers;
22        (2) N-[1(2-thienyl)
23   methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
24   its optical isomers, salts, and salts of isomers.
25    (h) Synthetic cathinones. Unless specifically excepted,
26any chemical compound not including bupropion, structurally

 

 

HB3680- 21 -LRB100 10855 RLC 21089 b

1derived from 2-aminopropan-1-one by substitution at the
21-position with either phenyl, naphthyl, or thiophene ring
3systems, whether or not the compound is further modified in one
4or more of the following ways:
5        (1) by substitution in the ring system to 
6    any extent with alkyl, alkylenedioxy, alkoxy, 
7    haloalkyl, hydroxyl, or halide substituents, whether 
8    or not further substituted in the ring system 
9    by one or more other univalent substituents. 
10    Examples of this class include, but are not 
11    limited to, 3,4-Methylenedioxycathinone 
12    (bk-MDA); 
13        (2) by substitution at the 3-position 
14    with an acyclic alkyl substituent. Examples of 
15    this class include, but are not limited to, 
16    2-methylamino-1-phenylbutan-1-one 
17    (buphedrone); or 
18        (3) by substitution at the 2-amino nitrogen 
19    atom with alkyl, dialkyl, benzyl, or methoxybenzyl 
20    groups, or by inclusion of the 2-amino nitrogen atom 
21    in a cyclic structure. Examples of this class include, 
22    but are not limited to, Dimethylcathinone, Ethcathinone, 
23    and a-Pyrrolidinopropiophenone (a-PPP). 
24(Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
2510-25-16.)